Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3101381 | 0.90 | KMT2A (0.39) | SMN1; SMN2NPC1HPGDRAB9AEPHX2 | |
| SCHEMBL3109222 | 0.88 | SMN1; SMN2 (0.40) | SMN1; SMN2NPC1ALDH1A1HPGDRAB9A | |
| SCHEMBL3102067 | 0.78 | KMT2A (0.39) | SMN1; SMN2NPC1HPGDRAB9AEPHX2 | |
| SCHEMBL3104458 | 0.76 | KMT2A (0.38) | SMN1; SMN2NPC1HPGDRAB9AEPHX2 | |
| SCHEMBL3108936 | 0.75 | KMT2A (0.40) | SMN1; SMN2NPC1HPGDRAB9AEPHX2 | |
| SCHEMBL3107066 | 0.74 | SMN1; SMN2 (0.44) | SMN1; SMN2NPC1ALDH1A1HPGDRAB9A | |
| SCHEMBL3094147 | 0.73 | GCGR (0.49) | SMN1; SMN2NPC1HPGDRAB9AMEN1 | |
| SCHEMBL3107118 | 0.72 | SMN1; SMN2 (0.35) | SMN1; SMN2NPC1HPGDRAB9AKMT2A | |
| SCHEMBL3110265 | 0.72 | GCGR (0.47) | SMN1; SMN2NPC1ALDH1A1HPGDRAB9A | |
| SCHEMBL3110015 | 0.71 | GCGR (0.47) | SMN1; SMN2NPC1HPGDRAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2210876-B1 | HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST | TAKEDA PHARMACEUTICAL (JP) | 2015-05-20 | — | — | EP | disclosed |
| US-8309580-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2210876-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | GLP1R, GPR119, GCGR | SMN1; SMN2 4692/4885NPC1 3994/4885ALDH1A1 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.